EDAP Announces Details on Termination Agreement With HealthTronics LYON, France, April 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production,
From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer UroToday.com announced today the addition of Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results
EDAP TMS S.A. to Release 2007 First Quarter Results LYON, France , May 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution
European RPP Program on Target for 2008 Profitability; FDA Trial Launch Positions EDAP for Direct USA Control; EDAP, China Medical Alliance Unites HIFU Leaders